The Fujifilm Corporation is not often thought of as a leader in anti-cancer drug development. Yet, oncology has become one of the company’s leading R&D efforts, leveraging its proven technological savvy for synthesizing and designing chemical compounds and analysis technologies to create novel anti-cancer drug compounds that promise to target some of the deadliest cancers in the world today. As part of Fujifilm’s new round of clinical trials, the company will tap MD Anderson to test three of its leading anticancer agents — FF-10501, FF-10502 and FF-21101 — as its first major step toward developing anticancer drugs in the United States.
The phase I clinical trial for FF-10501, which targets Hematological cancer and was developed through uncovering new mechanisms of action and identifying biomarker candidates for verifying efficacy, is set to start next spring at MD Anderson, and will follow a similar Phase I clinical trial conducted last May in Japan with patients with relapsed or refractory myelodysplastic syndromes.
FF-10502, a treatment for Pancreatic cancer, among others, seeks to offer excellent efficacy and enhanced production adaptability due to its highly efficient synthetic process. Finally FF-21101, which focuses on Lung cancer, conjugates antibodies with radioisotope for enhanced efficacy.
Considering that Fujifilm appears to be moving aggressively toward launching its oncology division of the company, choosing MD Anderson, the world’s leading Cancer research and treatment center, would appear to be an effective means of compiling the highest quality data on the efficacy of their new drugs, as well as putting their new compounds into the spotlight. With over 10,000 patients on therapeutic clinical trials each year and some 20,000 employees, the institution’s sheer size and focus on the clinical trial side of cancer research makes it an ideal candidate for Fujifilm, and will facilitate speedy and seamless clinical tests in Phase I and Phase II to gain a Proof of Concept at an early stage.
Results from the clinical trials are bound to be forthcoming. Stay tuned to BioNews Texas for continuing coverage.
The clinical trial at MD Anderson Cancer Center will be organized in cooperation with Boston Strategics Corporation. Cooperation with BSC, which boasts a global network of experts in pre-clinical and clinical development, Fujifilm will adopt a next-generation global clinical development model, flexibly forming a taskforce for each project rather than establishing a large-scale in-house R&D unit for clinical testing, for efficient R&D.